Navigation Links
Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, TX December 6-10, 2011. The poster presentations describe data generated on Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) platform, which enables efficient CTC capture and detection, as well as biomarker analysis on the captured CTCs (e.g., HER2, ER and PR status), as demonstrated in the posters.  These data represent findings from several studies involving blood and bone marrow samples from patients with breast cancer.

Farideh Bischoff, PhD, Vice President of Translational Research at Biocept, said, "Our posters present data that demonstrates our ability to detect estrogen receptor in CTCs, which can be clinically useful in patients for whom a biopsy is not feasible, and validation for HER2 FISH analysis performed on CTCs that are cytokeratin (CK) positive and, more importantly, CK negative.  Additionally, a collaborative poster presented with colleagues from the MD Anderson Cancer Center compares the detection of HER2 gene amplification in CTCs in blood and disseminated tumor cells (DTCs) in bone marrow in patients with non-metastatic breast cancer.  We think that Biocept's OncoCEE-BR™ assay for breast cancer, used for these studies, is ideal for the immunocytochemical, cytogenetic and molecular characterization of CTCs and DTCs, may be an important and clinically significant tool."  

Additional details for the SABCS presentations are as follows:

Wednesday, Dec 7, 5:00 – 7:00 PM (PI-07-13)
Efficiency of a Laboratory Developed HER2 FISH Test on Circulating Tumor Cells

Friday, Dec 9, 7:00 AM – 9:00 AM (P 4-06-03)
Detection of HER2 gene amplification in circulating tumor cells and disseminated tumor cells by fluorescence in situ hybridization using OncoCEE™

Friday, Dec 9, 5:00 PM – 7:00 PM (P5-01-08)
Immunocytochemistry staining of estrogen receptor in circulating tumor cells as compared to primary tumor

About Biocept, Inc.

Biocept, headquartered in San Diego, California, is an advanced diagnostic services company that operates a CLIA-certified, CAP-accredited testing laboratory specializing in the capture, detection, enumeration and molecular analysis of circulating tumor cells (CTCs). Biocept is dedicated to positively impacting the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes innovative and proprietary technologies to deliver clinically relevant and actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive with respect to different therapies, which may provide physicians with information to better treat their patients with cancer.

Biocept's CEE™ Platform

Biocept is developing the proprietary CEE™ (cell enrichment and extraction) platform, and a family of specialized CTC tests (OncoCEE™), which will be provided as a service to physicians and patients, as well as pharmaceutical and biotechnology companies, through Biocept's CLIA laboratory.  The CEE™ platform is comprised of microfluidic capture channels and associated instrumentation, antibody capture cocktails, CEE-Enhanced™ staining technology and biomarker assays performed on CTCs captured in the channels.  CTCs are extremely rare, and may be present in only 1 of every 50-100 billion blood cells, which is why their capture is challenging.  Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead of relying on traditional biopsy methods or surgical procedures. Samples are drawn into Biocept's unique CEE-Sure™ tubes, and shipped to its testing laboratory.

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
2. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BRâ„¢ Utilizing Circulating Tumor Cells (CTCs)
3. Biocept, Inc. Announces New CFO
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New Director Appointment - September 28, 2010
6. Biocept, Inc. Announces Two New Director Appointments
7. Biocept, Inc. Announces CEO and Director Appointments
8. MU signs academic agreement with K.S.R. Educational Institutions of India
9. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
10. GeoVax Labs CSO and Chairman Receive Academic Honors
11. deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers
Post Your Comments:
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and ... as Chief Operating Officer. , Having joined InSphero in November 2013 as ... promoted to Head of InSphero Diagnostics in 2014. There she has built up ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
Breaking Biology News(10 mins):